INSULIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS

Exchanging asparagine in the A21 position of insulin into another amino acid gives novel insulin derivatives which are more stable and less immunogenic than the patent compound. The insulin derivatives can be prepared by transpeptidation of a biosynthetic precursor which may be expressed in a host o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MARKUSSEN, J, JORGENSEN, K H, NORRIS, K, LANGKJAER, L
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Exchanging asparagine in the A21 position of insulin into another amino acid gives novel insulin derivatives which are more stable and less immunogenic than the patent compound. The insulin derivatives can be prepared by transpeptidation of a biosynthetic precursor which may be expressed in a host organism such as a yeast.